Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (531-540 of 744) with videos related to

Pageof 75
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 21, 2018
Diagnostic value of <sup>18</sup>F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary siteFabian Wolpert, Michael Weller, Anna Sophie Berghoff, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
The genetic evolution of acral melanomaMeng Wang, Satoshi Fukushima, Yi-Shuan Sheen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialPeter Mohr, Axel Hauschild, Uwe Trefzer, et al.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
Cancer Cell|July 17, 2018
EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma FormationDaniel Zingg, Julien Debbache, Rodrigo Peña-Hernández, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2009
MEK1 mutations confer resistance to MEK and B-RAF inhibitionCaroline M Emery, Krishna G Vijayendran, Marie C Zipser, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton, Marco Gerlinger, Olga de la Rosa, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Cell Stem Cell|April 6, 2019
Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma FormationSandra Varum, Arianna Baggiolini, Luis Zurkirchen, et al.
Nature Cancer|August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanomaFlorentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
Pageof 75

Showing results (531-540 of 744) with videos related to

Sort By:
Pageof 75
European Journal of Cancer (Oxford, England : 1990)|April 21, 2018
Diagnostic value of <sup>18</sup>F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary siteFabian Wolpert, Michael Weller, Anna Sophie Berghoff, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
The genetic evolution of acral melanomaMeng Wang, Satoshi Fukushima, Yi-Shuan Sheen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialPeter Mohr, Axel Hauschild, Uwe Trefzer, et al.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
Cancer Cell|July 17, 2018
EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma FormationDaniel Zingg, Julien Debbache, Rodrigo Peña-Hernández, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2009
MEK1 mutations confer resistance to MEK and B-RAF inhibitionCaroline M Emery, Krishna G Vijayendran, Marie C Zipser, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton, Marco Gerlinger, Olga de la Rosa, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Cell Stem Cell|April 6, 2019
Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma FormationSandra Varum, Arianna Baggiolini, Luis Zurkirchen, et al.
Nature Cancer|August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanomaFlorentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
Pageof 75